Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Reports on Transcept Pharmaceuticals

Sort by

Transcept: Throwing in the Towel on Intermezzo (TSPT, $3.56)

Thursday, May 9, 2013 · 12:02 pm

Read More

Transcept: The Prescription Trend Watch for Intermezzo is On (TSPT, $6.63)

Friday, February 15, 2013 · 10:02 am

Read More

Transcept: Purdue Fires Big Marketing Guns and FDA Issues Insomnia Drug Guidelines That Help Intermezzo (TSPT, $5.72)

Monday, January 21, 2013 · 10:52 am

Read More

The Launch of Transcept's Intermezzo by Purdue Has Begun (TSPT, $10.92)

Tuesday, April 24, 2012 · 4:23 pm

Read More

Investors' Concern About Launch of Intermezzo Weighs on the Stock and Creates a Buying Opportunity (TSPT, $8.21)

Tuesday, January 24, 2012 · 2:05 pm

Read More

Transcept to Resubmit Intermezzo NDA; Hopes for a Class I Review (TSPT, $6.63)

Thursday, September 15, 2011 · 1:27 pm

Read More

Intermezzo is Likely to be Approved on its July 14, 2011 PDUFA Date; Then What (TSPT, $7.98)

Sunday, July 10, 2011 · 11:00 am

Read More

Transcept Releases Results of Highway Driving Study for Intermezzo and Plans to Re-Submit NDA in the First Quarter of 2011 (TSPT, $6.61)

Saturday, June 4, 2011 · 8:50 am

Read More

There are 8 reports on file.

« Back to Company Reports Index